Balkrishna Industries - Export Base To Turn Favorable From Coming Months: ICICI Securities

Revival in agri segment tyres and relatively lesser exposure to U.S. should bode well.

Balkrishna Industries Ltd. (Source: Company official website)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

Indian off-highway-tyres exports improved sequentially by 12% in July 2023 (in line with average monthly exports in CY23), though were down ~20% YoY.

Agri segment exports increased 4% month-on-month to ~$85 million as against off-the-road segment exports at their highest in CY23 at $52 million, up 27% month-on-month.

Export base may reduce substantially Aug’23 onwards, resulting in YoY decline quantum shrinking from the current elevated levels for both the segments. Elevated base in U.S. OTR continued to impact segmental numbers and we expect that to persist till CY23 end.

In agri segment, too, U.S. base would remain elevated till CY23 end, though base for Europe would become favorable from Aug-23 itself.

For Balkrishna Industries, we maintain our estimates with 'Add' rating. We revise our target price (discounted cash flow based) to Rs 2,669 (earlier Rs 2,577), implying 26.5 times FY25E earnings per share.

Downside risks

Weakness in retail offtake from key markets would impact volume offtake for Balkrishna Industries in coming quarters, post weak volumes in the past few quarters due to inventory destocking.

Inability to grab further market share in global OHT market due to intense rise in competition.

Inability to go back to 28% operating margin level due to adverse input cost scenario and higher competition.

Click on the attachment to read the full report:

ICICI Securities Balkrishna Industries Company Update.pdf
Read Document

Also Read: Glenmark Pharma - Life Sciences Unit Stake Sale To Drive Considerable De-Leverage: Motilal Oswal

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

lock-gif
To continue reading this story
Subscribe to unlock & enjoy your
Subscriber-Only benefits
Still Not convinced?  Know More
Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.
GET REGULAR UPDATES